NASDAQ: SILOSilo Pharma Inc Stock
$1.08+0.05 (+4.85%)
Updated Apr 17, 2025
SILO Price
$1.08
Fair Value Price
$0.65
Market Cap
$4.82M
52 Week Low
$0.77
52 Week High
$4.50
P/E
-0.9x
P/B
0.96x
P/S
45.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$72.10k
Earnings
-$4.39M
Gross Margin
91.9%
Operating Margin
-6,085.54%
Profit Margin
-6,092.6%
Debt to Equity
0.47
Operating Cash Flow
-$4M
Beta
0.53
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SILO Overview
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SILO's potential to beat the market
- SILO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SILO
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SILO news, forecast changes, insider trades & much more!
SILO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SILO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SILO ($1.08) is overvalued by 66.16% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SILO ($1.08) is not significantly undervalued (66.16%) relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SILO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SILO due diligence checks available for Premium users.
Valuation
SILO fair value
Fair Value of SILO stock based on Discounted Cash Flow (DCF)
Price
$1.08
Fair Value
$0.65
Overvalued by
66.94%
SILO ($1.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SILO ($1.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SILO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SILO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.9x
Industry
-177.72x
Market
27.98x
SILO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
4.05x
SILO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SILO's financial health
Profit margin
Revenue
$18.0k
Net Income
-$1.7M
Profit Margin
-9,600.7%
SILO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SILO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.4M
Liabilities
$2.4M
Debt to equity
0.47
SILO's short-term assets ($7.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SILO's short-term assets ($7.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SILO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SILO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$917.4k
Investing
-$37.7k
Financing
$0.0
SILO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SILO vs Biotech Stocks
Silo Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.